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Abstract
Background and Aims Obesity associated with diabetes mellitus is a significant worldwide problem associated with considerable
health care costs.Whilst surgical intervention is effective, it is invasive, costly and associated with complications. This study aims
to evaluate the safety and efficacy of the EndoBarrier®, a duodenal-jejunal sleeve bypass as an alternative treatment of diabetes
mellitus in obese patients.
Materials and Methods This was a multi-centre, non-randomised trial recruiting obese patients with type 2 diabetes from three
sites in the UK. Eligible participants had a BMI of 30–50 kg/m2 and HbA1c levels of 7.5–10%. The study comprised a 12-month
period with the EndoBarrier® inserted and a 6-month follow-up period after it had been explanted. The primary study outcomes
were weight, BMI, HbA1c levels and fasting insulin and glucose levels.
Results Forty-five patients were recruited and 31 patients (69%) completed the 12-month study period. Significant reductions in
weight (95%CI 0.62–29.38; p < 0.05) and BMI (95%CI 1.1–8.7; p < 0.005) were documented 12 months after device insertion.
The mean HbA1c was significantly reduced (95%CI 0.1–1.6; p < 0.05) after the device insertion period and reductions in
metabolic parameters (fasting insulin and glucose levels) were also documented during the study. Adverse events were also
assessed in all patients, the vast majority of which were reported as mild.
Conclusions The EndoBarrier® appears to be a safe and effective treatment strategy in overweight patients with poor glycaemic
control despite medical therapy, or in those who are eligible but decline bariatric surgery.
Keywords Obesity . Type 2 diabetes . Bariatric surgery .
Bypass surgery . Duodenal-jejunal sleeve
Introduction
Obesity is a modern pandemic. One of the major complica-
tions of obesity is the development of diabetes; the US Centre
for Disease Control found that 85% of newly diagnosed type 2
diabetics were overweight or obese and 54% obese [1].
Obesity-associated diabetes mellitus leads to considerable
mortality, morbidity and enormous health care costs. In the
UK, obesity is estimated to consume 1.5% of the NHS budget
with an additional 10% of the budget spent on diabetes care. In
the USA, medical costs directly related to diabetes complica-
tions for the year 2006 were estimated at $22.9 billion. It is
thus a critical concern for global health care.
Medical therapy to control diabetes can be disappointing.
Only half of patients with diabetes achieve a satisfactory con-
trol measured by the glycosylated haemoglobin levels
(HbA1c) on medical treatment, whilst surgical interventions
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are more effective, but are not widely provided [2]. At present,
surgery is the only treatment that delivers sustainable weight
loss and glycaemic control [3, 4] in obese patients.
Hyperglycaemia can improve within days of surgery and be-
fore significant weight loss has occurred [5], suggesting the
role of weight-independent mechanisms of enhancing glucose
metabolism.
The Roux-en-Y gastric bypass (RYGB) operation was first
performed as a bariatric procedure in the 1960s[6] (minimally
invasively/laparoscopically since the 1990s) and delivers
sustained weight loss and resolution of obesity-related comor-
bidities, including type 2 diabetes [7]. In view of its clinical
efficacy, it remains among the most preferred bariatric proce-
dures in obese patients with type 2 diabetes mellitus.
Following RYGB, ingested food enters the jejunum via a
small stomach pouch, thereby bypassing the majority of the
stomach, the duodenum and the proximal 25–50 cm of the
jejunum, and achieves a number of immediate physiological
effects. These include bile flow alteration, reduction of gastric
size, anatomical gut rearrangement and alteration of flow of
nutrients, vagus nerve manipulation and enteric gut hormone
shifts (the so-called BRAVE effects) that subsequently result
in several downstream effects such as microbiota modulation,
adipokine release and alteration in glucose metabolism.
Gastric bypass can be performedwith a low 30-day in-hospital
mortality rate of 0.3% [8]. The superior effects of RYGB in
initial weight loss compared with gastric banding and sleeve
gastrectomy are postulated to be due to its multiple physiolog-
ical effects. These include reduced hunger, increased satiety
and, as more recently described from pre-clinical and clinical
studies, beneficial effects on taste and food preference away
from high-calorie foods [9, 10]. Whilst bariatric surgery can
be performed safely, there is a higher complication risk in
patients with diabetes and or obesity by virtue of these condi-
tions themselves, co-morbidities and their associated therapies
such as antiplatelet medication. These include general post-
surgical medical complications such as pneumonia and ve-
nous thrombosis (pulmonary embolism and deep vein throm-
bosis). Post-operative complications such as anastomotic dis-
ruption leading to leaks and fistulae [11], stomal stenosis [12],
dumping syndrome and diarrhoea are also problematic.
The duodenal-jejunal sleeve bypass (DJSB) or
EndoBarrier® (GI Dynamics Inc., Lexington MA) is an en-
doscopically implantable and removable device that is an-
chored in the first part of the duodenum, where it is attached
by a nitinol stent anchor to a 60-cm long polymer sleeve. The
sleeve prevents ingested food from coming into contact with
the mucosa of the proximal upper intestine. The design of the
DJSB therefore offers functional similarities to mimic some of
the physiological effects of Roux-en-Y gastric bypass. These
include exclusion of food from the proximal small intestine
and mixing of pancreatic and biliary juices after food passes
through the sleeve. Initial studies in humans have been for a 6-
month implant duration, with 6 months’ follow-up data, and
have also shown between 11.9 and 23.6% of total bodyweight
loss [13, 14] with improvements in diabetes including reduc-
tion in HbA1c and normoglycaemia [15, 16].
The aim of this prospective study was to assess the safety
and efficacy of the EndoBarrier® in obese patients with type 2
diabetes over an 18-month period, with a 12-month implant
duration, and then 6 months follow-up.
Materials and Methods
Study Design and Participants
This was a non-randomised study conducted at three investi-
gational sites (Southampton, London and Manchester) in the
UK to determine the performance of the EndoBarrier® for the
treatment of obesity and type 2 diabetes. The study was con-
ducted in accordance with Standard ISO 14155:2003 on clin-
ical investigations withmedical devices as well as the Helsinki
Declaration. Ethics committee approval was granted prior to
commencement of the study and any protocol deviations re-
ported. All patients provided written informed consent.
Recruitment
Subjects were recruited from hospital and community-based
diabetes clinics. Eligible study participants aged between 18
and 65 years with a history of diabetes and duration of 1–
10 years were invited to an initial assessment. This comprised
of baseline measures including demographic data, diabetes
and medical history and medication history. Baseline blood
tests including HbA1c, insulin and lipid profile were also
performed.
Key Inclusion and Exclusion Criteria
Participants who fulfilled the inclusion criteria and none of the
exclusion criteria were enrolled into the study (Table 1). The
key inclusion criteria included:
& Subjects with HbA1c level of 7.5 to 10% (58.5–
85.5 mmol/mol)
& Subjects with a BMI of 30 to 50 kg/m2
& Subjects taking oral type 2 diabetic medication and/or
insulin
The key exclusion criteria included:
& Subjects requiring > 150 units of insulin/day
& Subjects with fasting C peptide serum < 1.0 ng/mL
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& Subjects takingDPP4 inhibitors or incretins e.g. sitagliptin
or exenatide
& Subjects with type 1 diabetes or history of ketoacidosis
Once written consent was obtained, subjects were enrolled
in a nutritional counselling programme delivered by specialist
dieticians. The aim of the nutritional counselling programme
was to provide study participants with lifestyle and behaviour
modification, an understanding of calorific intake limitation
and good eating practices. Subjects were given advice regard-
ing liquid/modified diet for the first few weeks following im-
plantation. Subjects were tested for Helicobacter pylori and if
positive were prescribed eradication therapy. Subjects were
prescribed a proton pump inhibitor (omeprazole 40 mg BID)
to be taken from 3 days prior to device insertion and then
continued until 2 weeks after explant.
Study Period
The study period was 18 months in total; study participation
was considered complete at this point. Clinical and biochem-
ical assessments were carried out at baseline then 3, 6, 9 and
12 months and then post-device insertion. Device insertion
was performed under general anaesthetic with X-ray screen-
ing. Explant was performed either under general anaesthetic or
sedation and with X-ray screening at 12 months. Further as-
sessments were then conducted at 15 and 18 months—for 3
and 6 months post-explant (PE) with body mass index (BMI),
medication history and blood tests taken at each visit. Patients
were also asked to fill out a health questionnaire at the start
and end of the study. Details regarding health in general and
limitations of activity due to physical and emotional health
were documented. An assessment of mood, pain and sequelae
of physical or emotional problems was reported. All authors
had access to the study data and have reviewed and approved
the final manuscript.
Diabetes Management
Study subjects had their dose of insulin and sulphonylureas
reduced by 50% at the time of insertion to avoid
hypoglycaemic episodes. Metformin doses were reduced by
50% only if the fasting glucose was less than 3.9 mmol/L. Re-
introduction or dose modifications of diabetic medication
were made at the local study investigator’s discretion if inad-
equate glycaemic control during the study was noted.
The study investigators assessed the subjects for adverse
events throughout the study including unscheduled visits.
Subjects were withdrawn from the study if they, the sponsor
or the investigator requested it, if the subject was lost to
follow-up or if an adverse event required device explant and
study withdrawal.
Adverse Events
Safety measures were reported by evaluating the incidence
and severity of adverse events at each study assessment visit.
The adverse event, system it affected e.g. gastrointestinal tract,
dates of onset and resolution were documented. The severity
of the event was established and agreed by both patient and
clinician. Details regarding unscheduled gastroscopies,
changes in medication, other medical treatments and all hos-
pital admissions were also determined. Severe adverse events
were recognised to be a serious deterioration in the subject’s
health and included hospital admissions, medical or surgical
intervention and life-threatening conditions.
Statistical Analysis
Statistic and data syntheses were performed in Microsoft
Excel for Mac Version 14.4.4 (Microsoft Corporation,
Redmond, WA, USA) and Stata Version 12 (Stata Corp LP,
TX, USA).
Results
Study Population
A total of 45 subjects were enrolled into the study; 31 patients
(69%) completed the 12-month study period. A summary of
Table 1 Baseline characteristics for the implanted population
Subjects (n = 45)
Age, mean ± SD, years 49.9 ± 7.9
Gender, n (%)
Male 22 (48.9)
Female 23 (51.1)
Race: Caucasian, n (%) 40 (88.9)
Weight, mean ± SD, kg 115.0 ± 21.0
BMI, mean ± SD, kg/m2 40.0 ± 5.8
HbA1c, mean ± SD (%) 8.5 ± 0.8
Duration of diabetes, mean ± SD, years 4.6 ± 2.8
Glucose, mean ± SD, mmol/L 9.5 ± 2.95
Insulin, mean ± SD, mIU/L 18.8 ± 10.41
Total cholesterol, mmol/L 4.3 ± 0.97
Systolic BP, mmHg 141 ± 20
Diastolic BP, mmHg 82 ± 10
Comorbidities, n (%)
Hypertension 29 (64.4)
Hyperlipidaemia 32 (71.1)
Coronary artery disease 1 (2.2)
Sleep apnoea 3 (6.7)
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baseline characteristics and subject demographics is shown in
Table 1. A list of patient co-morbidities was obtained from
their general practitioner including date of diabetes onset and
prescribed medication.
Device Insertion Period
The device was successfully inserted in all cases; the mean
insertion time was 27 min and fluoroscopic time 7 min. There
were no procedure-related complications at insertion and all
devices were explanted successfully (Fig. 1). There was one
explant-related complication described below relating to the
endoscope cap which was resolved without removal of the
device and with no subsequent complications.
Adverse Events
Forty of the 45 study patients (88.9%) reported 127 device-
related adverse events from their individual completed study
period (Table 2). The vast majority of patients (38 (84.4%))
experienced mild device-related events. Table 2 outlines all
adverse events (described as mild, moderate or severe) expe-
rienced by study participants, with detailed reporting on gas-
trointestinal disturbances such as abdominal pain or discom-
fort, constipation, diarrhoea and dyspepsia which accounted
for most of the device-related adverse events. Thirty-eight
patients (84.4%) experienced at least one gastrointestinal ad-
verse event: ten patients (22.2%) reported 12 procedure-
related adverse events, 7 (15.6%) of which were classified as
mild including nausea, vomiting and pharyngolaryngeal pain.
Fourteen patients reported serious or severe adverse events
during the study period, all of which had completely resolved
at the end of the study. Of these, four patients complained of
severe abdominal pain and were admitted between 2 and
4 days. One patient was treated for constipation with laxatives,
one patient was found to have gallstones and required a cho-
lecystectomy and one was admitted for observation after a
normal gastroscopy. The final patient with abdominal pain
was found to have a device that had migrated greater than
3 cm and hence had the device explanted. One patient was
found to have upper gastrointestinal bleeding with erosions
found on gastroscopy and required removal of the device. In
one patient, the explant endoscope cap was lodged in the
pharynx and required removal of the cap (but not the device)
under general anaesthetic. This accounts for the only
procedure-related event reported during the study.
There were eight patients with serious adverse events not
relating to the study that required hospital admission. These
were for conditions including atrial flutter, myocardial infarc-
tion, musculoskeletal pain, urinary tract infection, gout, deep
vein thrombosis (DVT), respiratory compromise and possible
stroke. In all these cases, the patient had complete resolution
of the events.
Study Withdrawals
A full data set was collated for all 45 patients at baseline.
Thirty-one patients completed the 12-month study period; this
data was included for analysis. Fourteen subjects withdrew
from the study before 12 months; most of these did not attend
subsequent appointments and were ultimately lost to follow-
up (Table 3). The device was explanted early in 6 out of the 14
cases (Table 4). Two of these participants had device-related
adverse events requiring premature explant for melaena and
devicemigration resulting in abdominal pain respectively. The
other participants developed the unavoidable complications of
gout requiring non-steroidal anti-inflammatory medication
and vascular complications including myocardial infarction,
DVT and a transient ischaemic at tack requir ing
anticoagulation or antiplatelet medication. Both of these are
contraindications to the EndoBarrier® and hence resulted in
device explant. The number of patients who withdrew from
the study at different time intervals is shown in the table
below.
Three subjects withdrew from the study before 3 months,
three between 3 and 6 months, one between 6 and 9 months
and three between 9 and 12months due to adverse events. One
patient withdrew due to side effects from omeprazole, one
Fig. 1 Flow chart demonstrating the number of patients involved in the
study and study withdrawals
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withdrew as they were non-compliant with gliclazide and two
subjects requested to leave the study (Table 4).
The participant who did not complete the study due to non-
compliance with gliclazide suffered from fatigue, continuous
back pain and mild lower respiratory tract infection and
cholelithiasis. All of these conditions were mild with no clear
onset and only the fatigue was felt to be possibly device relat-
ed. The two subjects who requested to withdraw from the
study reported a number of mild to moderate adverse events
including nausea, vomiting, constipation, abdominal pains
Table 2 Adverse events classed by system or organ with an expansion on gastrointestinal disorders reported from all 45 study participants
Adverse events by system or organ Device Procedure Non-device
or procedure
Pre-existing At least 1 adverse
event experienced
n (%) n (%) n (%) n (%) n (%)
Blood and lymphatic system disorders e.g. anaemia 5 (11.1) 0 (0.0) 0 (0.0) 0 (0.0) 5 (11.1)
Cardiac disorders e.g. myocardial infarction 0 (0.0) 0 (0.0) 2 (4.4) 0 (0.0) 2 (4.4)
Gastrointestinal disorders 32 (71.1) 3 (6.7) 14 (31.1) 2 (4.4) 38 (84.4)
Abdominal discomfort 7 (15.6) 0 (0.0) 0 (0.0) 0 (0.0) 7 (15.6)
Abdominal distension 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.2)
Abdominal pain 5 (11.1) 0 (0.0) 2 (4.4) 0 (0.0) 7 (15.6)
Abdominal pain lower 1 (2.2) 0 (0.0) 2 (4.4) 0 (0.0) 3 (6.7)
Abdominal pain upper 13 (28.9) 3 (6.7) 0 (0.0) 2 (4.4) 18 (40.0)
Colonic polyp 0 (0.0) 0 (0.0) 1 (2.2) 0 (0.0) 1 (2.2)
Constipation 4 (8.9) 0 (0.0) 2 (4.4) 0 (0.0) 6 (13.3)
Diarrhoea 4 (8.9) 0 (0.0) 5 (11.1) 0 (0.0) 9 (20.0)
Duodenal ulcer 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.2)
Duodenitis 0 (0.0) 0 (0.0) 1 (2.2) 0 (0.0) 1 (2.2)
Dyspepsia 4 (8.9) 0 (0.0) 1 (2.2) 0 (0.0) 5 (11.1)
Epigastric discomfort 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.2)
Flatulence 3 (6.7) 0 (0.0) 0 (0.0) 0 (0.0) 3 (6.7)
Food poisoning 0 (0.0) 0 (0.0) 2 (4.4) 0 (0.0) 2 (4.4)
Gastroesophageal reflux disease 0 (0.0) 0 (0.0) 2 (4.4) 0 (0.0) 2 (4.4)
Irritable bowel syndrome 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.2)
Melaena 1 (2.2) 0 (0.0) 0 (0.0) 1 (2.2) 2 (4.4)
Nausea 5 (11.1) 0 (0.0) 3 (6.7) 0 (0.0) 8 (17.8)
Oesophageal polyp 0 (0.0) 0 (0.0) 1 (2.2) 0 (0.0) 1 (2.2)
Rectal haemorrhage 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.2)
Reflux gastritis 0 (0.0) 0 (0.0) 2 (4.4) 0 (0.0) 2 (4.4)
Stomach discomfort 1 (2.2) 0 (0.0) 0 (0.0) 0 (0.0) 1 (2.2)
Vomiting 7 (15.6) 0 (0.0) 1 (2.2) 0 (0.0) 8 (17.8)
General disorders e.g. pyrexia, fatigue 7 (15.6) 1 (2.2) 4 (8.9) 1 (2.2) 12 (26.7)
Hepatobiliary disorders 1 (2.2) 0 (0.0) 2 (4.4) 0 (0.0) 3 (6.7)
Infections and infestations e.g. cellulitis 1 (2.2) 0 (0.0) 12 (26.7) 0 (0.0) 13 (28.9)
Injury, poisoning and procedural complications e.g. vomiting 10 (22.2) 1 (2.2) 5 (11.1) 0 (0.0) 15 (33.3)
Metabolism and nutrition disorders e.g. iron deficiency 18 (40.0) 0 (0.0) 1 (2.2) 0 (0.0) 19 (42.2)
Musculoskeletal and connective tissue disorders 7 (15.6) 1 (2.2) 15 (33.3) 1 (2.2) 21 (46.7)
Blepharal papilloma 0 (0.0) 0 (0.0) 1 (2.2) 0 (0.0) 1 (2.2)
Nervous system disorders e.g. CVA 1 (2.2) 0 (0.0) 3 (6.7) 0 (0.0) 4 (8.9)
Psychiatric disorders e.g. depression 0 (0.0) 0 (0.0) 5 (11.1) 1 (2.2) 6 (13.3)
Renal and urinary disorders 0 (0.0) 0 (0.0) 1 (2.2) 0 (0.0) 1 (2.2)
Reproductive system and breast disorders 1 (2.2) 0 (0.0) 1 (2.2) 0 (0.0) 2 (4.4)
Respiratory, thoracic and mediastinal disorders e.g. apnoea 0 (0.0) 3 (6.7) 3 (6.7) 0 (0.0) 6 (13.3)
Skin and subcutaneous tissue disorders 2 (4.4) 0 (0.0) 1 (2.2) 0 (0.0) 2 (4.4)
Vascular disorders e.g. DVT 1 (2.2) 2 (4.4) 1 (2.2) 2 (4.4) 6 (13.3)
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and continuous rib and back pain that were felt to possibly be
device related. One participant suffered a moderate rectal
haemorrhage 197 days after the device was inserted and was
felt to be device related; the other participant suffered a severe
urinary tract infection that was felt to be possibly device
related.
Thirteen out of the 14 patients who withdrew did not attend
their 3-month PE or further appointments for data collection.
Three more patients did not attend their 6-month PE appoint-
ment for data collection. Data was hence collected for a
differing number of study subjects for both 3 and 6 months
PE for each study indicator. Data from between 28–31 patients
and 24–27 patients 3 and 6 months PE was available from the
full data set and between 24–26 and 19–23 patients from the
completer population 3 and 6 months PE respectively.
Study Parameters
Weight and BMI
During the device insertion period, both weight and BMI were
significantly reduced from baseline values with both parame-
ters at their lowest point 12 months after insertion. The mean
weight loss was 15 kg (95%CI 0.62–29.38; p < 0.05)
12 months after the device was inserted. Weight loss was most
rapid within the first 3 months of insertion (baseline 115.6 ±
21.1 kg (mean ± SEM), 3 months 106.2 ± 20.5 kg; difference
9.4 kg (95%CI − 4.6 to 23.4; p = ns)) (Fig. 2a).
BMI was reduced by 4.9 kg/m2 (95%CI 1.1–8.7;
p < 0.005) 12 months after device insertion and by 4.6 kg/m2
(95%CI 0.8–8.3; p < 0.005) from baseline. Significant reduc-
tions in BMI from baseline to 6, 9 and 12 months were ob-
served (mean difference 3.97 kg/m2 (95%CI 0.12–7.82;
Table 3 The number of participants and withdrawals at the main study
intervals
Number of study
months completed
Number of study
participants involved in
the study (%)
Cumulative number of
study participants who
withdrew from study
(%)
0, study baseline 45 (100) 0 (0)
3 42 (93.3) 3 (6.7)
6 38 (84.4) 7 (15.5)
9 35 (77.8) 10 (22.2)
12, study completed 31 (68.9) 14 (31.1)
Table 4 Study withdrawals including early device explants
Study
withdrawals/
non-completers
Reason for
withdrawal
Day of onset
post device
insertion
Severity Device related or pre-
existing/independent cause
Device
explanted early
1 Intermittent upper
abdominal pain
205 Severe Device related No
2 Abdominal pain 140 Moderate Device related (device
migration)
Yes
3 Atrial flutter 68 Moderate Pre-existing/independent No
4 Abdominal pain 28 Moderate Possibly device related No
5 Aggression 266 Mild Other—due to omeprazole
side effects
No
6 Possible transient
ischaemic attack
requiring aspirin
284 Moderate Pre-existing/independent Yes
7 Non-compliant
with gliclazide
N/A N/A N/A No
8 Gout 273 Severe Pre-existing/independent Yes
9 Myocardial
infarction
22 Moderate Pre-existing/independent Yes
10 Subject requested
to withdraw
from study
N/A N/A N/A No
11 Subject requested
to withdraw
from study
N/A N/A N/A No
12 Abdominal pain 2 Moderate Device related No
13 Gastrointestinal
bleeding
28 Moderate Device related Yes
14 Deep vein
thrombosis
11 Moderate Possibly related to device
implant/explant procedure
Yes
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p < 0.05), 4.6 kg/m2 (95%CI 0.634–8.57; p < 0.05) and
4.90 kg/m2 (95%CI 1.08–8.71; p < 0.005) respectively) (Fig.
2b).
Following explant, weight increased by 2.2 ± 5.1 kg at
3 months and 3.1 ± 5.2 kg at 6 months (Fig. 2a). Non-
significant increases from baseline BMI were noted at 3 and
6 months PE (increase of 1.0 kg/m2 (95%CI − 5.1 to − 3.1;
p = ns) and 1.6 kg/m2 (95%CI − 5.7 to 2.6; p = ns) respective-
ly). In addition, neither of these values were significant when
compared with BMI at the time of explant (Fig. 2b).
HbA1c
HbA1c was significantly reduced from baseline values during
the 12-month device insertion period. At 12 months, the mean
HbA1c was 0.8% below the mean at baseline (95%CI 0.1–
1.6; p < 0.05) (Fig. 3). A significant reduction in HbA1c was
seen as early as 3 months after insertion (0.9% decrease
(95%CI 0.1–1.6; p < 0.05)). This was further increased to
1.0% reduction at 6 months (p < 0.005) and 1.2% reduction
at 9 months (p < 0.00001).
Following explant, HbA1c levels remained stable; the
mean HbA1c was 7.7 ± 1.3% at 3 months and 7.7 ± 1.1% at
6 months. This equated to a mean difference from baseline of
0.7 ± 0.3% (p = ns) and 0.8 ± 0.3% (p = ns) (Fig. 3).
Fasting Plasma Insulin and Glucose
Reductions in both plasma insulin and glucose levels were
observed during the device insertion period. Fasting plasma
insulin levels had reduced by 4.4 mu/L (95%CI − 3.1 to 11.9;
p = ns) (Fig. 4a) and fasting plasma glucose reduced by
1.5 mmol/L (95%CI − 0.1 to 3.1; p = ns) measured 12 months
after insertion (Fig. 4b).
There was no change in fasting plasma insulin observed
between baseline and 6 months post-explant 0.71 miU/L
(95%CI − 8.53 to − 7.11; p = ns) (Fig. 4a). A reduction of
0.8 mmol/L (95%CI − 0.91 to 2.50; p = ns) in fasting glucose
was observed from baseline to 6 months after explant (Fig.
4b).
Changes in Medication
The majority of patients were taking metformin and
sulphonylureas for their diabetes; one patient required insulin
(Table 5).
Approximately 28% of patients taking metformin had their
dose of the drug reduced or discontinued 6 months after de-
vice insertion (Table 6) which was similar after 12 months.
Approximately 28% of patients taking sulphonylureas had
their dose reduced or discontinued the drug 6 months after
device insertion. This increased to 31% after 12 months.
Conclusion
This is the largest cohort of patients thus far described that had
an EndoBarrier® implanted for 12 months. Significant reduc-
tions in weight, BMI and glycaemic control were observed
during the device insertion period. The largest improvements
for most parameters were noted within 3 months after device
Fig. 2 Weight (a) and BMI (b) measurements at all time points from
baseline (pre-operative) to post-explant follow-up
Fig. 3 Measured values of HbA1c at all time points
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insertion, further but modest improvements in metabolic pa-
rameters continued between 3 and 12 months. Device inser-
tion benefits were maintained at 6 months post-explant with
small but non-significant metabolic parameter changes after
explant.
Whilst the EndoBarrier® was in place, doses of both
sulphonylureas and metformin were either reduced or, in a
third of the subjects, the medications were discontinued.
These reductions in pharmacotherapy coincided with reduc-
tions in HbA1c, fasting insulin and glucose. The largest and
most significant reduction in weight was observed at
12 months suggesting continued negative energy balance
whilst the device was implanted. This is in contrast to the
usual plateau reached at 3–6 months with lifestyle and phar-
macotherapy approaches.
Interestingly, the post-explant period did not show a prom-
inent rebound effect or reversal of the metabolic benefits ac-
crued during the period when the EndoBarrier® was in place.
Safety
Published experience based on 271 EndoBarrier® implanta-
tions have shown the device to have a favourable safety pro-
file [17]. In keeping with this, this study reported only one
procedure-related event caused by the explant endoscope cap
rather than the device itself. No other serious events were
described. Outside the USA, serious adverse events included
migration (4.9%), sleeve obstruction (3.4%) and liver abscess
(0.126%). The U.S. EndoBarrier® clinical therapy (the
ENDO Trial) was discontinued in July 2015 due to a 3.5%
incidence of hepatic abscesses [16]. The aetiology of this has
not been clearly established but may have resulted from local-
ised seeding of infection from the foreign device to the liver or
obstruction of the ampulla of Vater. This study reports no such
events. Furthermore, the majority of the adverse effects report-
ed were mild and the device well tolerated overall showing the
EndoBarrier® to be both a safe and effective device.
Limitations
This study reports the largest group of study participants with
type 2 diabetes and obesity that have had the EndoBarrier®
Fig. 4 Fasting plasma insulin (miU/L) (a) and fasting plasma glucose
(IU) (b) at all time points from baseline to post-explant follow-up
Table 5 Baseline medication for diabetes
Diabetes medication at baseline Number of patients (%)
Acarbose 1 (2.2)
Gliclazide 16 (35.6)
Glimepiride 2 (4.4)
Insulin 1 (2.2)
Metformin 40 (88.9)
Pioglitazone 4 (8.9)
Table 6 Changes in diabetic medication during the 12-month device
insertion period
Change in diabetes medication Months post-EndoBarrier® insertion
6 months 12 months
Sulphonylureas, n (%) n = 36 n = 45
Increased 1 (2.8) 1 (2.2)
No change 6 (16.7) 8 (17.8)
Decreased 3 (8.3) 3 (6.7)
Discontinued 7 (19.4) 11 (24.4)
N/Aa 19 (52.8) 17 (37.8)
Missing 0 (0) 5 (11.1)
Metformin, n (%) n = 36 n = 45
Increased 0 (0) 2 (4.4)
No change 24 (66.7) 21 (46.7)
Decreased 9 (25.0) 8 (17.8)
Discontinued 1 (2.8) 5 (11.1)
N/Aa 2 (5.6) 2 (4.4)
Missing 0 (0) 7 (15.6)
a Not taking at baseline
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inserted. The results show a beneficial effect on weight loss
and improvement in diabetes; however, the number of sub-
jects is not sufficient to evaluate safety comprehensively and
may be a limitation of the study. The results generated from
data obtained from the completer population suggest the de-
vice is safe and effective over 12months.Most of the literature
to date outlines short-term results from smaller studies with
limited follow-up. Our study reports mid-term outcomes, but
future studies should include longer term outcomes and safety
profiles for wider uptake of the device and establishment of
the device efficacy. This study did not include a diet control
group but it provides the effect size of benefits we can expect
to allow a future randomised placebo-controlled trial to be
powered appropriately.
Six out of the 14 patients who withdrew from the study
required premature EndoBarrier® removal. Of these, only
two patients presented with device-related complications (ab-
dominal pain due to device migration and gastrointestinal
bleeding); the others withdrew due to independent mainly
vascular medical adverse events. Cardiovascular disease is
the leading cause of mortality in patients with diabetes, with
an increased risk of developing myocardial infarction, periph-
eral vascular disease, stroke and heart failure [18]. Tight
glycaemic control has been shown to improve microvascular
diabetes-related complications; however, similar improve-
ments in primary cardiovascular events have not been demon-
strated [19, 20]. This suggests this population remains at risk
of cardiovascular events in the short term despite improve-
ments in glycaemic control following EndoBarrier® insertion.
Unfortunately, this increased risk usually requires prophylac-
tic antiplatelet therapy, a contraindication to device insertion
rendering the patient unsuitable for EndoBarrier® and limit-
ing the wider uptake of the device.
One patient developed deep vein thrombosis requiring
anticoagulation therapy, also a contraindication to device in-
sertion and hence required premature explant. Patients with
diabetes have been shown to be at increased risk of thrombo-
embolic events [21] possibly as a result of impaired fibrinoly-
sis and plasma hypercoagulability. Confounding risk factors
also present in this population include higher BMI,
dyslipidaemia and inflammation which will continue to in-
crease the risk of thromboembolic events, at least in the
short-term after device insertion. Additionally, although all
patients in this study had straightforward implantation proce-
dures, it is important to note that there are patients with a short
duodenal bulb length in whom the device may not be inserted
securely and be at risk of device migration, rotation and fail-
ure. Finally, medication was discontinued as a safety precau-
tion as to prevent hypoglycaemia, but future studies may aim
to continue drugs like metformin to obtain better glycaemic
control.
For patients, health care providers and commissioners
alike, a clearer understanding of the mechanisms involved in
improving glycaemia after such interventions is essential and
better data is required. The EndoBarrier® appears to work by
allowing bile to have undiluted contact with the proximal
small bowel mucosa, blocking food having contact with the
proximal small bowel mucosa and by changes in gut flora and
gut hormones. There are a number of potential metabolic con-
sequences of the device insertion such as an increase in satia-
tion potentially due to changes in gut hormones such as PYY,
GLP-1 and oxyntomodulin. Other potential changes may in-
clude increases in diet-induced thermogenesis and change in
taste and food preference. Further studies could investigate
whether the EndoBarrier® confers a specific metabolic advan-
tage in patients with type 2 diabetes by assessing whether and
to what extent it replicates the BRAVE effects of bariatric
surgery and its downstream sequelae, and how this might
improve glucose-mediated insulin release and/or reducing
liver-specific insulin resistance. The efficacy of the device
for each obesity class could also be determined in future
studies.
Increasingly, patients and physicians are looking towards
minimally invasive techniques as an alternative to convention-
al surgery to treat chronic diseases. The EndoBarrier® is a
device easily implanted and explanted without incisions, re-
ducing complications, time, cost and recovery associated with
conventional treatment modalities. Any measures to reduce
these whilst maintaining or improving the patient treatment
experience and post-procedure quality of life by the omission
of surgery should be further explored. This study shows the
EndoBarrier® to be a safe and effective device for the treat-
ment of obesity associated with type 2 diabetes.
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